TITLE:
Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis

CONDITION:
End-Stage Kidney Disease

INTERVENTION:
Zemplar (paricalcitol injection)

SUMMARY:

      To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for
      the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney
      disease on hemodialysis as measured by time to death.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 20 Years to N/A
Criteria:

        Stage V Chronic Kidney Disease Patients on Hemodialysis requiring treatment for secondary
        hyperparathyroidism with vitamin D therapy
      
